Anatara Lifesciences Ltd (ASX: ANR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Anatara Lifesciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.17 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
213.38 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
-88.30%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Anatara Lifesciences Ltd (ASX: ANR)
Latest News
Share Market News
Why the Anatara (ASX:ANR) share price is rocketing 19% today
⏸️ Investing
5 multi-million dollar takeover targets
⏸️ Investing
Ham and pineapple could make Anatara Lifesciences Ltd the next CSL Limited
⏸️ Investing
10 stocks up by more than 50% in the past month
ANR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in North Melbourne, Australia.
ANR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 24 Apr 2025 | $0.01 | $0.00 | 0.00% | 5,000 | $0.01 | $0.01 | $0.01 |
| 23 Apr 2025 | $0.01 | $0.00 | 0.00% | 1,250,000 | $0.01 | $0.01 | $0.01 |
| 22 Apr 2025 | $0.01 | $0.00 | 0.00% | 7,909,836 | $0.01 | $0.01 | $0.01 |
| 17 Apr 2025 | $0.01 | $0.00 | 0.00% | 33,535,737 | $0.01 | $0.01 | $0.01 |
| 16 Apr 2025 | $0.01 | $0.00 | 0.00% | 535,328 | $0.01 | $0.01 | $0.01 |
| 11 Apr 2025 | $0.01 | $0.00 | 0.00% | 521,493 | $0.01 | $0.01 | $0.01 |
| 08 Apr 2025 | $0.01 | $0.00 | 0.00% | 62,000 | $0.01 | $0.01 | $0.01 |
| 07 Apr 2025 | $0.01 | $0.00 | 0.00% | 1,045,006 | $0.01 | $0.01 | $0.01 |
| 02 Apr 2025 | $0.01 | $0.00 | 0.00% | 475,930 | $0.01 | $0.01 | $0.01 |
| 01 Apr 2025 | $0.01 | $0.00 | 0.00% | 1,007,224 | $0.01 | $0.01 | $0.01 |
| 28 Mar 2025 | $0.01 | $0.00 | 0.00% | 1,000,000 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 23 Dec 2024 | David Brookes | Buy | 500,000 | $25,000 |
Participation in share purchase plan.
|
| 23 Dec 2024 | John Michailidis | Buy | 100,000 | $5,000 |
Participation in share purchase plan.
|
| 18 Nov 2024 | John Michailidis | Issued | 359,640 | $20,859 |
Issue of securities. 359,640 Performance Rights
|
| 09 Jul 2024 | Nicholas Haslam | Issued | 1,000,000 | $40,000 |
Issue of options.
|
| 09 Jul 2024 | John Michailidis | Issued | 1,000,000 | $40,000 |
Issue of options.
|
| 09 Jul 2024 | John Michailidis | Issued | 250,000 | $10,000 |
Placement.
|
| 09 Jul 2024 | David Brookes | Issued | 1,500,000 | $60,000 |
Placement.
|
| 09 Jul 2024 | David Brookes | Issued | 2,500,000 | $100,000 |
Issue of options. As per announcement on 12-07-2024
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Lionel Brookes | Executive ChairmanExecutive Director | Jun 2022 |
Dr Brookes has experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as an analyst. Brookes has since held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by Perkin Elmer Inc (NYSE:PKI) in June 2018. He has also Chaired the risk and audit committees in ASX listed companies. He is member of Risk Management Committee.
|
| Mr Jonathan William Lindh | Company SecretaryNon Executive director | Nov 2024 |
Mr Lindh has 15 years of legal and company secretarial experience. He has worked in private practice for Australian and international law firms, and for a boutique corporate advisory business. Jonathan has experience advising listed and unlisted private and public companies on a range of matters including mergers & acquisitions, divestments, capital raisings, joint ventures, supply/offtake agreements, foreign investment, corporate governance and corporate law issues. Jonathan has also served as company secretary of several ASX listed companies and other private and public companies operating in various industries.
|
| Mr John Michailidis | Chief Operating OfficerExecutive Director | Oct 2023 |
Mr Michailidis has over 30 years of experience in the healthcare, pharmaceutical and biotechnology industries both in Australia and internationally. He has a record in business transformation, entrepreneurship, translation and commercialisation of science organisations, government engagement and influence, effectiveness in research translation, business development and organisational responsibility
|
| Simon Erskine | Chief Development Director |
-
|
|
| John Michailidis | Chief Operator Officer |
-
|
|
| Michael West | Chief Scientific Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| RTL Group Investments Pty Ltd <The Rtl Investment A/C> | 22,000,000 | 11.41% |
| Ubs Nominees Pty Ltd | 16,642,732 | 8.63% |
| Scintilla Strategic Investments Limited | 8,000,000 | 4.15% |
| Himstedt & Co Pty Ltd <The Himstedt Family A/C> | 6,900,000 | 3.58% |
| Parma Corporation Pty Ltd | 5,576,771 | 2.89% |
| RTL Group Investments Pty Ltd <The Rtl Investment A/C> i | 5,000,000 | 2.59% |
| Mr Samuel Francis Hunter | 4,862,662 | 2.52% |
| John Dahlsen Superannuation Fund Pty Ltd | 4,200,000 | 2.18% |
| Mousetrap Nominees Pty Ltd <Michael Whiting Family A/C> | 3,953,053 | 2.05% |
| Mr Michael Andrew Whiting and Mrs Tracey Anne Whiting <Whiting Family S/F A/C> | 3,625,000 | 1.88% |
| Myeng Pty Ltd | 3,580,211 | 1.86% |
| Calama Holdings Pty Ltd <Mambat Super Fund A/C> | 3,371,940 | 1.75% |
| Symington Pty Ltd | 3,340,000 | 1.73% |
| Toucan Trading Pty Ltd | 3,097,955 | 1.61% |
| Longridge Partners Pty Ltd | 2,839,248 | 1.45% |
| Mr Brendan Phyland | 2,651,659 | 1.37% |
| Mr Andre Nicholas Marschke and Mrs Shaleah Ann Marschke <Anm S/F A/C> | 2,600,000 | 1.35% |
| Octifil Pty Ltd | 2,595,416 | 1.35% |
| Tarandi 1996 Pty Ltd <Dr Dl Brookes Super A/C> | 2,490,002 | 1.29% |
| Mr David Lionel Brookes and Mrs Elisabeth Mary Brookes <Dahlbrook Family A/C> | 2,300,000 | 1.19% |
